Kailo Medical strives to facilitate paperless workflow in all aspects of Radiology and Healthcare in general to improve overall patient care.
FREMONT, CA: Kailo Medical, a healthcare technology company with products that streamline structured reporting in the hospital setting, announced its integration with Medo, an Artificial Intelligence company dual-headquartered in Singapore and Edmonton. The integration will see Medo Thyroid integrated into Kailo's SonoReview product to make nodule classification quicker, simpler, and more accurate, ultimately leading to better outcomes for patients.
"Kailo's SonoReview is a powerful tool that streamlines structured reporting for radiologists worldwide," said Jessica Wilson, VP North America at Kailo Medical. "The integration of MEDO's AI technology has the potential to double patient throughput and enable technologists and radiologists to more accurately assess, categorize and diagnose radiology findings, doing away with unnecessary follow up testing that can bring patients anxiety and stress."
The collaboration with Medo leverages AI and machine learning to analyze, assess and categorize thyroid ultrasound imaging using TI-RADS classification, all powered by the structured reporting delivered by Kailo's SonoReview. The paired technologies enable technologists and radiologists to make more informed and confident decisions, standardize diagnoses and, over time, reduce the margin of error to deliver better health outcomes for all.
"MEDO.ai automates the mundane, difficult and subjective elements of exams - but this value is only truly realized when it's incorporated directly into the workflow of users, as demonstrated by this integration with SonoReview," says David Quail, Co-Founder at MEDO.ai. "The integration of the two solutions allows users to benefit from Kailo Medical's efficiency gains as well as MEDO's AI assistance, all seamlessly integrated within their workflow. The union of these two groundbreaking technologies is set to deliver a better user and patient experience."